growth factor [5] , and hepatocyte growth factor [6] , have medical problem with a high mortality rate. Efforts to shorten been shown to enhance the recovery of renal function the course of ARF might reduce this mortality. Since thyroxine or to improve the survival in ischemic ARF in animals.
has been shown in experimental models to shorten the course Atrial natriuretic peptide has also been shown to be of ARF, we designed a trial to determine if a defined course of thyroxine would alter the course or change the mortality of protective in experimental ARF [7, 8] . Several of these clinical ARF.
agents have subsequently been used in clinical trials but Methods. A prospective, randomized, placebo-controlled, have not proved successful in altering the course of ARF double-blind trial of thyroxine was carried out in patients with in patients, as they were in experimental models [9] [10] [11] [12] .
ARF. End points were the percentage requiring dialysis, the The administration of thyroid hormone following initipercentage recovering renal function, time to recovery, and mortality.
ation of ARF has been shown to be effective in promotResults. Fifty-nine patients were randomized to receive either ing recovery from ARF in a wide variety of ischemic thyroxine or placebo. The groups were well matched in terms and toxic models of ARF [13] [14] [15] [16] [17] . Following renal injury, of basal and entry creatinines, age, sex, APACHE II scores thyroid hormone was administered either as a single dose at entry, and percentage oliguric. Baseline thyroid functions, or over short time courses at amounts ranging from two including T 3 , T 4 , rT 3 , and thyroid stimulating hormone (TSH) levels, were equal between the two groups and typical of pato five times the normal replacement doses. Neither clinitients with euthyroid sick syndrome. Thyroxine resulted in a cal nor laboratory evidence of hyperthyroidism was eviprogressive and sustained suppression of TSH levels in the dent in treated animals. An uncontrolled clinical trial treated group, but had no effect on any measure of ARF severof thyroxine in a pediatric population reported that all ity. Mortality was higher in the thyroxine group than the control patients diuresed following therapy [18] . Although thygroup (43 vs. 13%) and correlated with suppression of TSH.
Conclusions. In contrast to the beneficial effects seen in roid hormone has not been tried in clinical ARF in adult experimental ARF, thyroxine has no effect on the course of demonstrated a major improvement in morbidity nor mortality in relatively small groups. The studies have also not been able to show significant evidence of major Acute renal failure (ARF) is a serious medical probadverse effects with the use of thyroid hormone in selem. Despite decades of improvement in supportive care, verely ill medical or surgical euthyroid patients. We the mortality of ARF in the hospitalized acutely ill patherefore undertook a prospective randomized trial of tient has changed little [1-3]. In contrast to this clinical thyroid hormone in the treatment of ARF to determine picture, work in experimental ARF has suggested several whether thyroid hormone altered the course or mortality promising therapeutic maneuvers, some of which have associated with ARF. resulted in the amelioration or reversal of ischemic or toxic ARF in animal models. A number of growth fac-reversible prerenal azotemia, defined as a fall in serum creatinine with correction of prerenal factors, (b) renal dence of allergy to the study drug. No patients were withdrawn from the study for any of these criteria. All patients were examined prior to the entrance in the study and appeared to be clinically euthyroid. The study was were age, sex, comorbid conditions (APACHE II), baseapproved by the Institutional Review Board for Biomedline creatinine concentration, presence of oliguria, thyical Research at the University of Pittsburgh (Pittsburgh, roid function studies, and treatment group assignment PA, USA). Informed consent was obtained for all pa-(thyroid or control). tients participating in the study.
All patients were evaluated by the same group of Patients were randomly assigned to receive intravenephrologists at the University of Pittsburgh Medical Cennous thyroxine (thyroid) or placebo (control); investigater (UPMC), and dialysis support was initiated for stantors were blinded to the group assignment. The protocol dard indications in the setting of ARF at this institution solution consisted of 150 g of thyroxine in 20 mL of as previously described [25] . Renal replacement therapy normal saline administered over five minutes by slow was either intermittent hemodialysis (HD) performed intravenous infusion. The placebo solution consisted of with modified cellulose dialyzers, either cellulose acetate 20 mL of normal saline. Solutions were administered or hemophane, or continuous venovenous HD (CVVDH) every 12 hours for 48 consecutive hours. The groups using polyacrilonitrile dialyzers. The choice of dialysis were treated and monitored in the intensive care unit mode was made on clinical grounds, and CVVHD was (ICU). At entry, demographic data, major diagnoses, primarily used for those patients who required pressor APACHE II score [23, 24] , and presence or absence of support. Some patients received both modes. oliguria (defined as urine output Ͻ400 mL/24 hours) Initial power analysis was carried out to ensure suffiwere documented. Thyroid function studies [thyroidcient power to detect differences between treatment stimulating hormone (TSH), free T 3 , free T 4 , and reverse groups. Because the course of renal failure might be T 3 (rT 3 )] were obtained at study entry and on days 1, 7, influenced with or without an effect on mortality, we and 14 after study entry.
assumed that mortality was the least sensitive while also End points of the study were patient mortality and the most reproducible outcome measure of ARF, and severity of renal failure. These were initially examined we used this outcome for the analysis. Because a retroseparately because of the possibility that thyroid might spective study at our institution gave an overall mortality affect one but not the other. Patients were followed until of 60% for ICU-acquired ARF [25] , the study plan was death or discharge from the hospital. To determine if to conduct a two-sided test to determine a 33% differthere was a survival advantage, the percentage of survival ence in mortality (that is, a decrease in mortality to for thyroid and control groups was compared using chi-40%). The chi-squared test for comparing two binomial square analysis with Yates correction. To examine the proportions was used for the analysis. The sample size effect of thyroid on the clinical course of ARF, five determined called for 97 subjects per group [26] . During measures of ARF severity were analyzed: (a) the percent the trial, the mortality response was monitored for early requiring dialysis, (b) the percent recovering renal funcdramatic benefits or potential harmful effects, using the tion, (c) the increase in serum creatinine concentration sequential method of Pocock [27] . The test statistic was from baseline, (d) the time from initiation of ARF to computed following data acquisition of the first 60 subearliest recovery (defined as increased urinary output or jects, without breaking the code by the investigators. decline in creatine without dialysis), and (e) the time Because a significant difference in mortality was obfrom initiation of ARF to stable recovery. Differences served at the first analysis, the trial was terminated. in the thyroid hormone measurements in the two groups over time were analyzed by analysis of variance supple-RESULTS mented by a one degree of freedom t-test if the signifiEntry characteristics for the thyroid and control groups cance was found by analysis of variance (ANOVA).
are shown in Table 1 . The groups were similar in age, Stepwise logistic regression was carried out with survival as the dependent variable. Predictors entered stepwise sex, APACHE II scores at enrollment, the percentage the study. In an attempt to characterize this potentially important marker further, we also compared survivors with nonsurvivors in terms of clinical factors (Table 6) . Survivors tended to be younger, have lower APACHE who were oliguric, and entry and baseline serum creatinine values. Consistent with our previous observations II scores, be less frequently oliguric, and have a less frequent requirement for dialysis than nonsurvivors. at this institution [25] , the majority of patients in both groups received total parenteral nutrition (TPN) during However, none of these differences reached statistical significance. Consistent with the results of the regression their stay in ICU, and the use of TPN was not different between the two groups (data not shown). Etiologies analysis, TSH at day 1 was the most robust discriminator between survival and death. of ARF, determined during clinical evaluation of the patients as the most likely primary cause of ARF, are Steroid and dopamine use have been reported to influence thyroid economy in critically ill patients [28, 29] . listed in Table 2 for the two groups. There was no significant difference between the two groups in terms of the We therefore examined steroid and dopamine usage in both groups within 48 hours prior to and following study distribution of major etiologic events for ARF. The thyroid function tests of the two groups are shown in Table  entry . Steroid and dopamine usage were similar for both 3. At the beginning of the study (day 0), all patients groups (control 71.7%, thyroid 57.1%, P ϭ NS). We also showed the same pattern of low T 4 , low normal TSH compared steroid and dopamine use between survivors levels, and elevated rT 3 levels typical of the euthyroid (with rising TSH levels) and nonsurvivors (with low TSH sick syndrome [28] . There were no significant differences levels). The use of steroids and dopamine within 48 hours in any of these measures between the two groups at the prior to and following study entry was similar between start of the study. The only significant changes in these survivors and nonsurvivors (Table 6 ). There were no measures during the course of the study were a fall in differences between the two groups. TSH levels in the thyroid group at days 1 and 7, and a rise in TSH levels in the control group throughout the DISCUSSION study period. The TSH level was significantly greater in Thyroid hormone (either T 3 or T 4 ) has been shown to control compared with the thyroid group at day 7.
be active in promoting recovery from ARF in a wide Outcomes of the two groups are shown in Table 4. variety of animal models [13] [14] [15] [16] [17] . A single, uncontrolled There was no significant difference between thyroid and trial in children suggested promising results [18] . Several control groups in any measure of severity of ARF. The studies report the use of thyroid hormone in adults in percentage requiring dialysis, time on dialysis, time to ICU settings with acute nonthyroidal illness [19] [20] [21] . earliest and stable recovery, and percentage of recovThese studies were prompted by a considerable body ering function were similar in both groups. There was a of clinical observations suggesting abnormalities in the significant difference in mortality between the two thyroid axis of the acutely ill, which have been charactergroups. Mortality was significantly higher in the thyroid ized as the euthyroid sick syndrome [28] . The hallmarks group. The mean time from entry to death for those who of this syndrome are low T 3 , low to normal T 4 , elevated died was not different between the two groups.
rT 3 , and normal TSH. The significance of these findings Stepwise regression analysis was undertaken to deterto outcome in severely ill patients is conjectural. Almine which clinical or laboratory characteristics best corthough apparently euthyroid by clinical measures, the related with mortality. Neither age, sex, APACHE II notion that these patients are truly euthyroid has been score, need for dialysis, creatinine at entry, presence questioned [30] . The value of thyroid hormone replaceof oliguria, or group assignment (thyroid or control) ment remains unknown [30] [31] [32] , but the studies so far correlated significantly with survival. The only significant performed in non-ARF patients have not shown a sigrelationship to outcome was with TSH level at day 1 of nificant effect on outcome, either positive or negative, in the trial. We therefore examined the relationship becritically ill adults. Our study demonstrates that patients tween TSH level and survival in more detail. Table 5 with ARF exhibit biochemical findings typical of the demonstrates the TSH levels for survivors and nonsurvivors at all points measured for both groups. TSH was euthyroid sick syndrome. Thyroid replacement in this Abbreviations are: S Cr (peak), maximal creatinine value; S Cr (recovery), creatinine level at renal recovery; Time/R1, time to initial decline in serum creatinine; Time/R2, time to stable creatinine level. Individual modalities of dialysis support are presented as % of total group and sum to equal overall % requiring any dialysis.
a P ϭ 0.01 by Fisher's exact test to result in a continued suppression of TSH, as control Data are shown as mean Ϯ sem or % of total per group. There were no patients exhibited a progressive rise in TSH throughout significant differences between groups in these parameters.
the study period. Although no other clinical or biochemical evidence of hyperthyroidism was noted in our population, the continued suppression of TSH correlated with though the numbers are small in this study, there was the poorer outcome for thyroid treated patients clearly no hint of an effect of renal failure. Along with insulinindicates that euthyroid sick patients should not be relike growth factor-1 (IGF-1) [10] and atrial natriuretic placed with thyroid hormone.
peptide (ANP) [9, 12] , this represents the third agent In contrast to the remarkable effects of thyroxine on that showed great promise in laboratory ARF but little experimental ARF, no effect on renal function or renal recovery was observed in our patient population. Aleffect in clinical ARF. The possible reasons for this have recently been discussed [11, 33] . This study relied on in circumstances considerably more complex than experchanges in serum creatinine and clinical maneuvers to imental models. Our experience underscores the need rule out prerenal states to identify true ARF. As a result, to conduct such trials with early and frequent monitoring renal failure was established and relatively severe by the of outcomes. Finally, our results suggest that derangetime therapy was begun. The serum creatinine was more ments in the thyroidal axis in critical illness may help to than double the baseline values at the time of entry into predict eventual patient outcome. Sustained suppression the study. These facts alone are not necessarily inconsisof TSH may identify a group of patients with increased tent with the rationale for thyroid hormone in ARF, as mortality [35] . it has been shown that thyroid is effective only after the untoward effects when applied in the clinical setting. was 13%, and in the thyroid group, mortality was 43%. The observed mortality in controls in this study was less and dopamine in established acute renal failure in the rat. Kidney than that typically seen at our institution [25] in ARF II scores tended to be somewhat lower than those deHintz R, Myers M, Haenftling K, Capra W, Pike M, Guler scribed in our previous study [25] . Although this might suggests that there may be a cause and effect association. mately require human trials that inevitably take place
